---

-------------------------------------------------------------------------
1.請符合以下文章格式，違者4-1刪除
2.本分類提供以下幾種文章搬運
        a. 每日交易數據相關：每日法人買買超、融資券、交易量...
        b. 公司重要訊息相關：營收、股利、股東會懶人包、法說會內容整理...
        c. 現有資訊整理相關：殖利率排名、金融股獲利分布、
3.請詳閱板規參考相關規定
----------------------------按ctrl+y可刪除以上內容。---------------------

1. 標題：10 Million Doses of mRNA-based COVID-19 Vaccine to be supplied to Taiwa
n Region



3. 網址：            


4. 內文：



SHANGHAI, CHINA and MAINZ, GERMANY, July 12, 2021 — BioNTech SE (Nasdaq: BNT
X, “BioNTech” or “the Company”) announced that Fosun Industrial Co., Limited
 (“Fosun Industrial”), a wholly owned subsidiary of its partner Shanghai Fosun
 Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 60
0196.SH, 02196.HK), has reached advance procurement agreements for the mRNA-ba
sed COVID-19 vaccine BNT162b2 with Taiwan Semiconductor Manufacturing Co., Ltd.
(“TSMC”), Hon Hai Precision Industry Co., Ltd. (“Hon Hai”), Yonglin Charity
Foundation ("Yonglin") and Zuellig Pharma, Inc. (“Zuellig Pharma”) respectivel
y. Fosun Industrial will sell a total of 10 million doses of COVID-19 mRNA vacci
nes to Zuellig Pharma (pharmaceutical company with qualifications to import vacc
ines) entrusted by TSMC, Hon Hai and Yonglin. These COVID-19 mRNA vaccines will
be donated to the relevant agency of disease control of the Taiwan region for lo
cal vaccination.


Ugur Sahin, M.D., CEO and Co-founder of BioNTech said, “It has always been our
 goal to provide access to a well-tolerated and effective vaccine for as many pe
ople as possible worldwide. BioNTech is glad to be able to also supply the Taiw
anese people with vaccines manufactured in the European Union. In parallel, BioN
Tech will continue to evaluate the vaccine for use against additional mutations
of concerns.”


Wu Yifang, Chairman and CEO of Fosun Pharma said, “We are glad to see that the
 vaccine co-developed by Fosun Pharma and BioNTech could play a positive role in
 the prevention and control of the epidemic in Taiwan. We will work closely with
 our partners to provide safe and effective vaccines to Taiwan at an early date,
 safeguarding the lives and health of Taiwan compatriots, and helping their life
 getting back on track as soon as possible.”

On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration.
 Fosun Pharma has been licensed by BioNTech to exclusively develop and commercia
lize COVID-19 vaccines based on its mRNA technology platform in Chinese Mainland
, Hong Kong SAR, Macau SAR and Taiwan region.



內文完全照抄上海復星的聲明

中翻英而已

總之就是恭喜台灣Region

購買BNT終於獲得原廠認可




--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 39.10.186.5 (臺灣)
※ 文章代碼(AID): #1Wx2VrtA (Stock)
※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1626089461.A.DCA.html